Acute psychostimulant challenge in primary obsessive-compulsive disorder

Journal of Clinical Psychopharmacology

Volumn 11, Issue 4, 1991, Pages 237-241

  Joffe, Russell T ^a   Swinson, Richard P ^a   Levitt, Anthony J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; DEXAMPHETAMINE; METHYLPHENIDATE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPULSION; FEMALE; HUMAN; MALE; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; BEHAVIOR; CENTRAL NERVOUS SYSTEM STIMULANTS; COMPARATIVE STUDY; DEXTROAMPHETAMINE; FEMALE; HUMAN; MALE; METHYLPHENIDATE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES;

EID: 0025820449     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/00004714-199108000-00003     Document Type: Article

References (33)

1. Rasmussen SA, Tsuang MT. Clinical characteristics and family history in DSM-III obsessive-compulsive disorder. Am J Psychiatry 1986;143:317–22.
2. Regier DA, Boyd JH, Burke JD Jr, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Locke BZ. One-month prevalence of mnental disorder in the United States. Arch Gen Psychiatry 1988;45:977–86.
3. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M. Obsessive-compulsive disorder: A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605–12.
4. Insel TR, Mueller EA, Gillin JC, Siever LJ, Murphy DL. Tricyclic response in obsessive-compulsive disorder. Prog Neuropsycho-pharmacol Biol Psychiatry 1985;9:25–31.
5. Insel TR, Murphy DL. The psychopharmacological treatment of obsessive-compulsive disorder: a review. J Clin Psychopharmacol 1981;1:304–11.
6. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 1985;20:1174–9.
7. Turner SM, Jacob RG, Beidel DC, Nathan RS. Fluoxetine treatment of obsessive compulsive disorder. J Clin Psychopharmacol 1985;5:207–12.
8. Insel TR, Hamilton JA, Guttmacher LB, Murphy DL. D-Amphetamine in obsessive-compulsive disorder. Psychopharmacology 1983;80:23–6.
9. Joffe RT, Swinson RP. Methylphenidate in primary obsessive-compulsive disorder. J Clin Psychopharmacol 1987;7:420–2.
10. Swinson RP, Joffe RT. Biological challenges in obsessive-compul-sive disorder. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:269–75.
11. Clemens JA, Fuller W. Differences in the effects of amphetamine and methylphenidate on brain dopamine turnover and serum prolactin concentration in reserpine-treated rats. Life Sci 1979;24:2077–81.
12. Kamal L, Arbilla S, Langer S. Presynaptic modulation of the release of dopamine from the rabit caudate nucleus: differences between electrical stimulation, amphetamine and tyramine. J Pharmacol Exp Ther 1981;216:592–8.
13. Kuczenski, R. Biochemical actions of amphetamines and other stimulants. In Stimulants: neurochemical, behavioural and clinical perspectives. New York: Raven Press, 1983:31–61.
14. Reigle TG, Isaac WL, Isaac W. Behavioural and neurochemical interactions of dextroamphetamine and methylphenidate in rats. J Pharmacol Sci 1981;70:816–8.
15. Scheel-Kruger J. Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain. Eur J Pharmacol 1971;14:47–59.
16. 3H-norepinephrine from rat brain via presynaptic mechanisms. Life Sci 1979;24:255–64.
17. Goldstein DS, Nurnberger J, Jr, Simmons S, Gershon ES, Polinsky R, Kerser HR. Effects of injected sympathomimetic amines on plasma catecholamines and circulatory variables in man. Life Sci 1983;32:1057–63.
18. Janowsky DS, Davis JM. Methylphenidate, dextroamphetamine, and levamphetamine. Arch Gen Psychiatry 1976;33:304–8.
19. Little KY. Amphetamine but not methlyphenidate, predicts antidepressant efficacy. J Clin Psychopharmacol 1988;8:177–83.
20. Smith RC, Davis JM. Comparative effects of D-amphetamine, L-amphetamine, and methylphenidate on mood in man. Psychopharmacology 1977;53:1–12.
21. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978;35:773–8.
22. Spitzer RL, Endicott J. Schedule for affective disorders and schizophrenia-life version (SADS-L) (3rd ed.) New York: New York State Psychiatric Institute, 1978.
23. Groff DC. The stimulant challenge test in depression. J Clin Psychiatry 1986;47:538–43.
24. Cooper J. The Leyton obsessional inventory. Psychol Med 1970;1:48–60.
25. Thoren P, Asberg M, Cromholm B. Clomipramine treatment of obsessive-compulsive disorder: a controlled clinical trial. Arch Gen Psychiatry 1980;37:1281–6.
26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–7.
27. Spielberger CD, Gorsuch RL, Luchene RE. STAI Manual for the State-Trait Anxiety Inventory. Palo Alto. CA: Consulting Psychiatrists, 1970.
28. SAS User’s Guide, Cary, NC: SAS Institute, Inc., 1980.
29. Little KY. Detecting acute drug effects. Biol Psychiatry 1989;25:645–7.
30. Kuczenski R, Segal DS, Leith NJ, Applegate CD. Effects of amphetamine, methylphenidate and apomorphine on regional brain serotonin and 5-hydroxyindole acetic acid. Psychopharmacology 1987;93:329–35.
31. Joyce PR, Nicholls NG, Donald RA. Methylphenidate increases heart rate, blood pressure and plasma epinephrine in normal subjects. Life Sci 1984;34:1707–11.
32. Zametkin AJ, Karoum F, Linnoila M, Rapoport JL, Brown GL, Chuang LW, Wyatt RJ. Stimulants, urinary catecholamines and indoleamines in hyperactivity: a comparison of methylphenidate and dextroamphetamine. Arch Gen Psychiatry 1985;42:251–5.
33. Innes RI. Action of dexamphetamine on 5-hydroxytryptamine receptors. Br J Pharmacol 1963;21:427–35.